{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:06:14Z","timestamp":1789736774971,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5-6","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.pharma.2008.09.002","type":"journal-article","created":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T04:22:26Z","timestamp":1225513346000},"page":"288-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nouvelles perspectives d\u2019utilisation des h\u00e9patocytes humains au cours du d\u00e9veloppement pr\u00e9clinique des m\u00e9dicaments"],"prefix":"10.1016","volume":"66","author":[{"given":"A.","family":"Guillouzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2008.09.002_bib1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1001\/jama.287.17.2215","article-title":"Timing of new black box warnings and withdrawals for prescription medications","volume":"287","author":"Lasser","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.pharma.2008.09.002_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1006\/rtph.2000.1399","article-title":"Concordance of the toxicity of pharmaceuticals in humans and in animals","volume":"32","author":"Olson","year":"2000","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.pharma.2008.09.002_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cbi.2004.09.009","article-title":"A comprehensive approach for drug safety assessment","volume":"150","author":"Li","year":"2004","journal-title":"Chem Biol Interact"},{"issue":"Suppl. 2","key":"10.1016\/j.pharma.2008.09.002_bib4","first-page":"511","article-title":"Liver cell models in in vitro toxicology","volume":"106","author":"Guillouzo","year":"1998","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.pharma.2008.09.002_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0309-1651(82)90187-4","article-title":"High yield preparation of isolated human adult hepatocytes by enzymatic perfusion of the liver","volume":"6","author":"Guguen-Guillouzo","year":"1982","journal-title":"Cell Biol Int Rep"},{"key":"10.1016\/j.pharma.2008.09.002_bib6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0026-895X(25)13247-1","article-title":"Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture","volume":"44","author":"Abdel-Razzak","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharma.2008.09.002_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0009-2797(97)00072-0","article-title":"Long-term primary cultures of adult human hepatocytes","volume":"107","author":"Ferrini","year":"1997","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.pharma.2008.09.002_bib8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0928-0987(01)00135-X","article-title":"Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation","volume":"13","author":"LeCluyse EL","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharma.2008.09.002_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-4827(83)90107-6","article-title":"Maintenance and reversibility of active albumin secretion by adult rat hepatocytes co-cultured with another liver epithelial cell type","volume":"143","author":"Guguen-Guillouzo","year":"1983","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.pharma.2008.09.002_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/hep.1840040305","article-title":"Long-term co-cultures of adult human hepatocytes with rat liver epithelial cells: modulation of albumin secretion and accumulation of extracellular material","volume":"4","author":"Clement","year":"1984","journal-title":"Hepatology"},{"key":"10.1016\/j.pharma.2008.09.002_bib11","first-page":"406","article-title":"Viability and function in primary culture of adult hepatocytes from various animal species and human beings after cryopreservation","volume":"18","author":"Chesne","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.pharma.2008.09.002_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1007690009927","article-title":"Viability and drug metabolism capacity of alginate-entrapped hepatocytes after cryopreservation","volume":"16","author":"Rialland","year":"2000","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.pharma.2008.09.002_bib13","first-page":"712","article-title":"An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant","volume":"29","author":"Andersson","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharma.2008.09.002_bib14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/03602539709002237","article-title":"Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices","volume":"29","author":"Houston","year":"1997","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.pharma.2008.09.002_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1124\/dmd.106.011569","article-title":"Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance","volume":"35","author":"Brown","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharma.2008.09.002_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0024-3205(87)90037-3","article-title":"Species differences in metabolism of ketotifen in rat, rabbit and man: demonstration of similar pathways in vivo and in cultured hepatocytes","volume":"40","author":"Le Bigot","year":"1987","journal-title":"Life Sci"},{"key":"10.1016\/j.pharma.2008.09.002_bib17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1432-1033.1990.tb19140.x","article-title":"Expression of cytochrome P-450 enzymes in cultured human hepatocytes","volume":"191","author":"Morel","year":"1990","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.pharma.2008.09.002_bib18","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1124\/dmd.104.000026","article-title":"Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance","volume":"32","author":"McGinnity","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharma.2008.09.002_bib19","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1073\/pnas.90.11.5123","article-title":"Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens","volume":"90","author":"Pfeifer","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2008.09.002_bib20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0014-5793(98)00746-7","article-title":"Re-expression of C\/EBP alpha induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells","volume":"431","author":"Jover","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharma.2008.09.002_bib21","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2008.09.002_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/dmd.105.006759","article-title":"Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells","volume":"34","author":"Aninat","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharma.2008.09.002_bib23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.21536","article-title":"Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor","volume":"45","author":"Cerec","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.pharma.2008.09.002_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0300-483X(02)00296-2","article-title":"Transporters and xenobiotic disposition","volume":"181\u2013182","author":"Kim","year":"2002","journal-title":"Toxicology"},{"key":"10.1016\/j.pharma.2008.09.002_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejps.2006.01.004","article-title":"Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line","volume":"28","author":"Le Vee","year":"2006","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharma.2008.09.002_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.pharma.2008.09.002_bib27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/toxsci\/kfl058","article-title":"Sequential exposure to cytokines reflecting embryogenesis: the key for in vitro differentiation of adult bone marrow stem cells into functional hepatocyte-like cells","volume":"94","author":"Snykers","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.pharma.2008.09.002_bib28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.exphem.2005.12.004","article-title":"Failure of hepatocyte marker-expressing hematopoietic progenitor cells to efficiently convert into hepatocytes in vitro","volume":"34","author":"Lian","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.pharma.2008.09.002_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1517\/17425255.1.1.61","article-title":"Generation of human hepatocytes by stem cell technology: definition of the hepatocyte","volume":"1","author":"Hengstler","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharma.2008.09.002_bib30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/ncb1132","article-title":"Hematopoietic stem cells convert into liver cells within days without fusion","volume":"6","author":"Jang","year":"2004","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharma.2008.09.002_bib31","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nbt1258","article-title":"BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm","volume":"24","author":"Gouon-Evans","year":"2006","journal-title":"Nat Biotechnol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450908001247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450908001247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:26:26Z","timestamp":1757719586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450908001247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":31,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0003450908001247"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2008.09.002","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelles perspectives d\u2019utilisation des h\u00e9patocytes humains au cours du d\u00e9veloppement pr\u00e9clinique des m\u00e9dicaments","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2008.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}